Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lixte Biotech Hlds (LIXT)

Lixte Biotech Hlds (LIXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,729
  • Shares Outstanding, K 7,477
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,590 K
  • EBIT $ -5 M
  • EBITDA $ -5 M
  • 60-Month Beta 0.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.62

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.45 +24.08%
on 02/11/26
4.01 -24.19%
on 01/29/26
unch (unch)
since 01/20/26
3-Month
2.45 +24.08%
on 02/11/26
4.80 -36.67%
on 11/28/25
-1.30 (-29.95%)
since 11/20/25
52-Week
0.64 +375.00%
on 06/18/25
6.26 -51.44%
on 09/12/25
+1.68 (+123.53%)
since 02/20/25

Most Recent Stories

More News
LIXTE Biotechnology (NASDAQ: LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical and med-tech company advancing cancer treatments, announced the appointment of Sidney Braun as Chief Executive Officer of its...

LIXT : 2.97 (-2.47%)
LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused...

LIXT : 2.97 (-2.47%)
LIXTW : 0.0221 (+4.74%)
LIXTE Biotechnology (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is focused on enhancing established cancer therapies by targeting a fundamental biological pathway involved in tumor...

LIXT : 2.97 (-2.47%)
LIXTE Biotechnology (NASDAQ: LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer Treatment

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that’s pioneering proton therapy systems for treating tumors in various...

LIXT : 2.97 (-2.47%)
LIXTE Biotechnology (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is leading efforts in addressing some of the pressing challenges in cancer treatment. “Instead of developing standalone...

LIXT : 2.97 (-2.47%)
Improving the Odds: How LIXTE Biotechnology (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective

Despite decades of progress in oncology, many cancers remain resistant to treatment, not because therapies are unavailable, but because tumor cells adapt. Immunotherapies and chemotherapies can produce...

LIXT : 2.97 (-2.47%)
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy

LIXTE Biotechnology (NASDAQ: LIXT) is a clinical-stage pharmaceutical company leading efforts in addressing some of the pressing challenges in cancer treatment. Instead of developing standalone cancer...

LIXT : 2.97 (-2.47%)
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Sponsors Good Health Mind, Body and Soul Summit

LIXTE Biotechnology Holdings (NASDAQ: LIXT) is sponsoring the inaugural Good Health: Mind, Body & Soul Summit, an invitation-only event inspired by the music, legacy, and lived experiences of De La Soul...

LIXT : 2.97 (-2.47%)
DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE

Event Sponsored by LIXTE Biotechnology Holdings, Developer of Breakthrough Cancer Therapies Atlanta, GA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspired by the music, legacy, and lived experiences...

LIXT : 2.97 (-2.47%)
LIXTW : 0.0221 (+4.74%)
LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29

BOCA RATON, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical-stage pharmaceutical company advancing LB-100, a...

LIXT : 2.97 (-2.47%)
LIXTW : 0.0221 (+4.74%)

Business Summary

Lixte Biotechnology Holdings Inc. is a drug discovery company which uses biomarker technology to identify enzyme targets associated with serious common diseases. The company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents...

See More

Key Turning Points

3rd Resistance Point 3.34
2nd Resistance Point 3.28
1st Resistance Point 3.16
Last Price 2.97
1st Support Level 2.98
2nd Support Level 2.92
3rd Support Level 2.80

See More

52-Week High 6.26
Fibonacci 61.8% 4.11
Fibonacci 50% 3.45
Last Price 2.97
Fibonacci 38.2% 2.79
52-Week Low 0.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar